Journal of Clinical Investigation · 2009 · 327 citations · 61 references
MedicineCancer BiologyOncologyMolecular OncologySignal TransductionTumor ProgressionApoptosis ResistanceCancer Cell SignalingMolecular Tumor ProfilingOncogenic Signaling PathwaysSignal Transduction In CancerTumor Suppressor GenesCancer Signaling PathwaysCanonical Wnt Beta-catenin PathwayCanonical Wnt PathwayHepatocellular Carcinoma PathogenesisMicroarray AnalysisMolecular Mechanisms Of CarcinogenesisNf-κb SignalingTissue Microarray Analysis
Hepatocellular carcinoma (HCC) is a highly aggressive vascular cancer characterized by diverse etiology, activation of multiple signal transduction pathways, and various gene mutations. Here, we have determined a specific role for astrocyte elevated gene-1 (AEG1) in HCC pathogenesis. Expression of AEG1 was extremely low in human hepatocytes, but its levels were significantly increased in human HCC. Stable overexpression of AEG1 converted nontumorigenic human HCC cells into highly aggressive vascular tumors, and inhibition of AEG1 abrogated tumorigenesis by aggressive HCC cells in a xenograft model of nude mice. In human HCC, AEG1 overexpression was associated with elevated copy numbers. Microarray analysis revealed that AEG1 modulated the expression of genes associated with invasion, metastasis, chemoresistance, angiogenesis, and senescence. AEG1 also was found to activate Wnt/beta-catenin signaling via ERK42/44 activation and upregulated lymphoid-enhancing factor 1/T cell factor 1 (LEF1/TCF1), the ultimate executor of the Wnt pathway, important for HCC progression. Inhibition studies further demonstrated that activation of Wnt signaling played a key role in mediating AEG1 function. AEG1 also activated the NF-kappaB pathway, which may play a role in the chronic inflammatory changes preceding HCC development. These data indicate that AEG1 plays a central role in regulating diverse aspects of HCC pathogenesis. Targeted inhibition of AEG1 might lead to the shutdown of key elemental characteristics of HCC and could lead to an effective therapeutic strategy for HCC.
61
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro et al. · New England Journal of Medicine · 2008 · 13K citations · Full text
Medicine, Oncology, Pharmacology +12
Ahmedin Jemal, Rebecca L. Siegel, Elizabeth Ward et al. · CA A Cancer Journal for Clinicians · 2008 · 10.2K citations · Full text
Sorafenib in Advanced Hepatocellular Carcinoma
재연 정 · 2008 · 5.6K citations
Medicine, Oncology, Pharmacology +12
Functional interaction of β-catenin with the transcription factor LEF-1
Jürgen Behrens, Jens Peter von Kries, Michael Kühl et al. · Nature · 1996 · 2.9K citations